Potential Effects of FGFR4 in the Helicobacter pylori–Induced Inflammatory Carcinoma Transformation

In the pathogenesis of gastric cancer, Helicobacter pylori infection was the most important risk factor for noncardia gastric cancer. Recently, the US Department of Health and Human Services had again identified H pylori as a human carcinogen in its 15th Report on Carcinogens,1 which has sparked global concern. However, the exact mechanism by which H pylori induces gastric carcinogenesis remains unclear. In their article in Gastroenterology, Zhang et al2 found a link between H pylori infection, inflammation, and fibroblast growth factor (FGF) receptor 4 (FGFR4) activation, where SRC mediated a feed-forward activation loop between FGFR4 and signal transducer and activator of transcription 3 (STAT3) in response to H pylori infection.

Leggi
Giugno 2022

RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Objectives
Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) and modified RECIST (mRECIST) are commonly used to assess tumour response. Which one is better to evaluate efficacy after molecular targeted therapies in hepatocellular carcinoma (HCC) patients is still controversial. A systemic review was performed to compare the objective response rate (ORR) and disease control rate (DCR) and a meta-analysis was conducted to compare the correlation between objective response and overall survival (OS).

Design
Systematic review and meta-analysis using the Grading of Recommendations Assessment, Development and Evaluation approach.

Data sources
EMBASE, PubMed, Web of Science and Cochrane Library were searched through 31 December 2021.

Eligibility criteria
We included studies assessing the efficacy of molecular targeted therapy for HCC according to both RECIST 1.1 and mRECIST.

Data extraction and synthesis
Two investigators extracted data independently. The consistency between RECIST 1.1 vs mRECIST is measured by the k coefficient. HRs with corresponding 95% CIs were used for meta-analysis.

Results
23 studies comprising 2574 patients were included in systematic review. The ORR according to mRECIST is higher than RECIST1.1 (15.9% vs 7.8%, p

Leggi
Giugno 2022